Company Filing History:
2 out of 1,244 
1 out of 321 
Years Active: 2012-2015
Title: Jae Ryoung Hwang: Innovator in Cancer Treatment
Introduction
Jae Ryoung Hwang is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of innovative treatments for cancer. With a total of 2 patents, his work focuses on utilizing specific peptides and antibodies to inhibit tumor growth and enhance therapeutic efficacy.
Latest Patents
Hwang's latest patents include groundbreaking inventions that target cancer treatment. One of his notable patents is the "Use of C-terminal domain of IGFBP-5 comprising heparin-binding domain as an angiogenesis inhibitor." This invention relates to a pharmaceutical composition designed to inhibit angiogenesis, which is crucial for tumor growth. It includes an isolated peptide derived from insulin-like growth factor-binding protein-5 (IGFBP-5) and outlines methods for using this peptide in cancer treatment.
Another significant patent is the development of "CD9-specific human antibodies." This invention focuses on a human antibody that recognizes the CD9 extracellular loop 2 domain as an epitope. The antibody exhibits a neutralizing effect on CD9 antigens and demonstrates the ability to inhibit tumor cell lines, making it a promising candidate for cancer therapies targeting CD9 overexpression.
Career Highlights
Throughout his career, Jae Ryoung Hwang has worked with esteemed institutions such as Sungkyunkwan University and the Korea Research Institute of Bioscience and Biotechnology. His research has been pivotal in advancing the understanding of cancer biology and developing novel therapeutic strategies.
Collaborations
Hwang has collaborated with notable colleagues, including Young Woo Park and So-Young Choi. These partnerships have contributed to the success of his research and the development of his patented inventions.
Conclusion
Jae Ryoung Hwang is a distinguished inventor whose work in cancer treatment through innovative peptides and antibodies has the potential to transform therapeutic approaches. His contributions to biotechnology continue to pave the way for advancements in cancer therapies.